Global Cardiac Biomarkers Market – Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2013-2017 and Forecast 2018-2024

Cardiac Biomarkers Market

 

Global Cardiac Biomarkers Market: By Biomarker Type (Natriuretic Peptides (BNP And NT-ProBNP), Ischemia Modified Albumin, Creatine Kinase, Myoglobin, Troponins (T,I), and Others), By Disease Type (Acute Coronary Syndrome, Congestive Heart Failure, Atherosclerosis, Myocardial Infarction, and Others), By End User (Laboratory Testing, Point of Care Testing), and Geography – Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2013-2017 and Forecast 2018-2024

 

Global cardiac biomarkers market was valued at US$ XX Mn in 2017 and expected to grow at XX% Compound Annual Growth Rate (CAGR) from 2018 to 2024

 

Market Outline: Cardiac Biomarkers Market

Cardiac biomarkers are the substances that usually released into the blood when the heart is stressed or damaged. They are helpful in the diagnosis of an acute coronary syndrome (ACS) and cardiac ischemia, and other conditions associated with insufficient blood flow to the heart. The test for cardiac biomarkers is used to determine an individual’s risk of having the above conditions.

 

Request Sample Report : https://bit.ly/2qJgVuC

 

 

Market Dynamics: Cardiac Biomarkers Market

Increase in the prevalence of cardiovascular diseases anticipated to drive the growth of the cardiac biomarkers market. According to the World Health Organization (WHO), cardiovascular diseases (CVDs) take the lives of 17.7 million people every year, 31% of all global deaths. Growing awareness among the people regarding the early diagnosis of the disease is expected to fuel the cardiac biomarkers market. The factors such as highly accurate results and point of care testing are driving the growth of the market. However, the poor reimbursement policies are likely to hamper the growth of the market. The stringent government regulations for test approvals are hindering the growth of the cardiac biomarkers market.

 

 

Market Scope: Cardiac Biomarkers Market

Cardiac biomarkers market is segmented based on the biomarker type, disease type, and end user

Based on the biomarker type, the market is segmented into the following:

  • Natriuretic Peptides (BNP And NT-ProBNP)
  • Ischemia Modified Albumin
  • Creatine Kinase
  • Myoglobin
  • Troponins (T,I)
  • Others

 

Based on the disease type, the market is segmented into the following:

  • Acute Coronary Syndrome
  • Congestive Heart Failure
  • Atherosclerosis
  • Myocardial Infarction
  • Others

 

Based on the end user, the market is segmented into the following:

  • Laboratory Testing
  • Point of Care Testing

 

Regional Analysis:  Cardiac Biomarkers Market

Geographically, global cardiac biomarkers market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America cardiac biomarkers market is the dominant market when compared with that of other regional markets owing to its deep-rooted healthcare infrastructure. The adoption of the modern diagnosis and treatment methods for cardiac disease is adding fuel for the growth of the market. Europe cardiac biomarkers market falls next to that of North America region in the global cardiac biomarkers market. The Asia Pacific cardiac biomarkers market is expected to grow over the forecast period owing to increase in the prevalence of the cardiac diseases. The developing healthcare infrastructure is adding fuel for the growth of the cardiac biomarkers market.

 

 

Competition Assessment: Cardiac Biomarkers Market

Some of the players in the global cardiac biomarkers market include:

  • Randox laboratories (UK)
  • Thermo Fisher Scientific (U.S)
  • Roche Diagnostics (Switzerland)
  • Abbott Laboratories (U.S)
  • Siemens Healthcare (Germany)
  • Alere Inc. (U.S)
  • Becton, Dickinson and Company (U.S)
  • Bio-Rad Laboratories (U.S)
  • BioMerieux (France)
  • Beckman Coulter (U.S)

 

Notable Market Developments: Cardiac Biomarkers Market

  • In January 2017, Roche has received 510(k) clearance for its Elecsys Troponin T Gen 5 STAT (TnT Gen 5 STAT) blood test for patients with a suspected heart attack.

 

For More Information:  https://www.precisionbusinessinsights.com/market-reports/cardiac-biomarkers-market/